The colonoscopy prep that's a pill. Not a liquid.
OsmoPrep Tablets change the way you experience a colonoscopy preparation. A colonoscopy prep previously meant drinking a lot of bad-tasting liquid. OsmoPrep makes your prep easier by
allowing you to take virtually tasteless tablets with your choice of clear liquids.
Discovering a colonoscopy prep with a difference.
Most people dread getting a colonoscopy and taking the prep—in fact, the bowel prep process is the top reason people avoid getting colonoscopies.1
However, an effective prep is necessary to get accurate results. When the colon is prepared adequately, a colonoscopy
may detect the early signs of colon cancer
. Research reports that more
than 50% of colon cancer deaths can be prevented with regular screening combined with a healthy lifestyle.2
What makes OsmoPrep different from liquid bowel preps, is the fact that it is a pill prep. This gives you the choice of
what clear liquid you take it with—many people seem to enjoy this freedom of choice. In clinical trials, 95% of people who took
OsmoPrep said they would choose it again.3
Talk to your healthcare provider about OsmoPrep.
Read through the OsmoPrep web site to learn more about this alternative to liquid preps, the prep process, colonoscopies,
and colon cancer
. If you have questions, ask your healthcare provider for additional information.
Learn more about OsmoPrep—The Tablet Colon Prep.
What happens during a colonoscopy procedure?
Important questions to ask your health care provider
Why do you need a bowel prep?
Important Safety Information about OsmoPrep
There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior
to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some
cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with
increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using
medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers
[ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).
It is important to use the dose and dosing regimen as recommended (PM/AM split dose).
Please see full Prescribing Information for OsmoPrep, including BOXED WARNING.
OsmoPrep® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing
of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OsmoPrep is used in
patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation,
bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal
function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte
disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as
hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OsmoPrep.
OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with
biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were
abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before,
during, and after the use of OsmoPrep.
- Harewood GC, Wiersema MJ, Melton LJ III. A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy. Am J Gastroenterol. 2002;97:3186-3194.
- Harvard Center for Cancer Prevention. Colon Cancer. Available at http://www.hsph.harvard.edu/cancer/cancers/colon/riskfactors/prevent_crc.htm. Accessed May 11, 2007.
- Rex DK, Schwartz H, Goldstein M, et al. Safety and colon-cleansing efficacy of a new residue-free formulation of sodium phosphate tablets. Am J Gastroenterol. 2006;101:2594-2604.